Literature DB >> 22504573

Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients.

Yi Li1, Xin Hu, Bei Cai, Jie Chen, Yangjuan Bai, Jiangtao Tang, Yun Liao, Lanlan Wang.   

Abstract

BACKGROUND: The published data revealed conflicting results of the polymorphism of MDR1 exon 26 SNP C3435T on the pharmacokinetics of tacrolimus in different post transplant times; thus, the aim was to perform a meta-analysis of different post transplant times to investigate the influence of SNP C3435T on the tacrolimus pharmacokinetics.
METHODS: A literature search was conducted to locate the relevant papers by using the PUBMED and EMBASE electronic source until 2011. The pharmacokinetic parameters, including dose administration, concentration and concentration to dose ratio were extracted and a meta-analysis was performed by using STATA10.0.
RESULTS: A total of 13 papers concerning 1327 individuals were included in the meta-analysis. The overall results showed SNP C3435T could influence the pharmacokinetic parameters in different post transplant times, the subjects with CC genotype had lower concentration dose ratio and need higher tacrolimus dose than the CT and TT genotype.
CONCLUSIONS: Our meta-analysis of available studies has demonstrated a definite correlation between the SNP C3435T in MDR1 gene and pharmacokinetics of tacrolimus. However, additional studies with large sample size and better study designs are warranted to verify our finding.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504573     DOI: 10.1016/j.trim.2012.03.006

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  8 in total

Review 1.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population.

Authors:  Wen-ying Shu; Jia-li Li; Xue-ding Wang; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

3.  Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.

Authors:  Nikola Z Stefanović; Tatjana P Cvetković; Tatjana M Jevtović-Stoimenov; Aleksandra M Ignjatović; Goran J Paunović; Radmila M Veličković
Journal:  Exp Ther Med       Date:  2015-06-26       Impact factor: 2.447

4.  Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor.

Authors:  Jonas W Højfeldt; Osvaldo Cruz-Rodríguez; Yasuhiro Imaeda; Aaron R Van Dyke; James P Carolan; Anna K Mapp; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2014-01-01

5.  Genetic determinants of renal transplant outcome: where do we stand?

Authors:  Paul J Phelan; Peter J Conlon; Matthew A Sparks
Journal:  J Nephrol       Date:  2014-02-11       Impact factor: 3.902

Review 6.  Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.

Authors:  Laure Elens; Dennis A Hesselink; Ron H N van Schaik; Teun van Gelder
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

Review 7.  Correlation between gene polymorphism and blood concentration of calcineurin inhibitors in renal transplant recipients: An overview of systematic reviews.

Authors:  Lan Su; Lu Yin; Jinkun Yang; Lin Sun
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 8.  ABCB1 in dermatology: roles in skin diseases and their treatment.

Authors:  H J Weng; T F Tsai
Journal:  J Mol Med (Berl)       Date:  2021-08-09       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.